Write a Comment

JamesC

Will be interesting to learn if relapses after bb2121 are due to a type of MDR that has classically driven breakthrough of treatment with PIs and IMIDs. If not, what else explains the drop off in remission rates after one year post-treatment? Also, I see no mention of adjunct therapy with IMIDs, PIs or MoAbs (or even dexamethasone). I will be interesting to know if this is feasible, valuable or ill-advised.

March 28, 2018 • Michigan